Brokerage : Shinhan Securities
Analyst : Minyong Eom, Hocheol Lee
Investment Rating : Not Rated
Target Price : –
Core Momentum : Enhanced clinical differentiation for ABL301 under Sanofi’s strategic trial refinement alongside pipeline scalability into genetic medicines and muscle shuttles for Grabody-B
📊 1. [Valuation & Key Financial Metrics]
- Investment Rating & Target Price: Not Rated (No Target Price provided), Current Price KRW 197,700 (As of Jan 30, 2026)
- Historical Financial Highlights:
- 2021: Revenue KRW 5.3 Billion, Operating Profit KRW -52.3 Billion, Controlling Interest Net Profit KRW -43.6 Billion, PBR 18.6x, ROE -77.8%
- 2022: Revenue KRW 67.3 Billion, Operating Profit KRW 0.9 Billion, Controlling Interest Net Profit KRW 3.2 Billion, PER 341.0x, PBR 15.8x, EV/EBITDA 328.8x, ROE 5.1%
- 2023: Revenue KRW 65.5 Billion, Operating Profit KRW -2.6 Billion, Controlling Interest Net Profit KRW -2.6 Billion, PBR 15.9x, ROE -3.7%
- 2024: Revenue KRW 33.4 Billion, Operating Profit KRW -59.4 Billion, Controlling Interest Net Profit KRW -55.5 Billion, PBR 9.7x, ROE -46.0%
- Stock Indicators: Market Cap KRW 10,932.4 Billion, Outstanding Shares 55.3 Million shares (Floating Ratio 75.1%), 52-Week High/Low KRW 245,500 / KRW 33,000, 60-Day Avg Daily Trading Value KRW 280,242 Million, Foreign Ownership 14.1%, Major Shareholders Sang Hoon Lee & 11 affiliated parties (24.9%)
🚀 2. [Market Opportunities & Business Outlook]
- Sanofi’s Strategic Rationale for ABL301:
- Sanofi’s pipeline ‘prioritization adjustment’ reflects a strategy to apply analytical methods directly verifying efficacy in follow-up trials, rather than termination (countering erroneous foreign media reports of ‘removal’).
- While competing alpha-synuclein assets (Roche’s prasinezumab, BioArctic’s exidavnemab) rely on indirect DaT scan diagnostics, Sanofi aims to demonstrate direct quantitative reduction of alpha-synuclein to establish Best-in-class positioning and reimbursement criteria.
- ABL301 represents a differentiated Parkinson’s disease candidate integrating the Grabody-B BBB penetration platform, unlike competing non-BBB-shuttle antibodies.
- Platform Scalability & Out-Licensing Catalysts:
- Executed KRW 8 Trillion in IGF1R platform licensing deals with GSK and Eli Lilly in 2025 (including equity investment by Eli Lilly).
- Additional licensing discussions were held at JPMHC 2026.
- Validation of Grabody-B for genetic medicines with Ionis is pending scientific publication, with further upside anticipated upon proof of scalability in obesity and muscle shuttle applications.
📝 Editor’s Comment (Perspective)
The covering analyst views ABL Bio not as an enterprise constrained by single-asset timeline recalibration, but as a leading biotech whose strategic partner refinement aims for definitive clinical superiority while its core Grabody-B platform expands across diverse therapeutic modalities. This perspective prioritizes Sanofi’s direct efficacy demonstration strategy and the structural platform scalability verified across major pharma collaborations (GSK, Lilly, Ionis) over short-term market sentiment.
To verify whether this investment thesis continues to materialize, primary focus should be directed toward the finalization of Sanofi’s refined clinical protocol for ABL301, the upcoming publication of research findings with Ionis regarding genetic medicine delivery, and the execution of new Grabody-B licensing agreements across obesity or muscle-targeting indications. These operational milestones can be monitored through partner disclosures, scientific publications, corporate IR updates, and official regulatory filings.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
